A US court cleared the path for a lawsuit accusing Bristol Myers Squibb of delaying FDA approval of Breyanzi to avoid milestone payments tied to its 2019 Celgene acquisition. The trustee suit, filed by plaintiffs on behalf of Celgene stakeholders, alleges the company slow-walked regulatory timing. The development raises reputational and potential financial exposure for BMS tied to an FDA decision that investors and clinicians have viewed as central to the company’s cell therapy growth strategy. It also underscores how acquisition-era milestone structures can translate into litigation risk long after launches. Legal outcomes will depend on further proceedings, but the case can affect how future acquisition contracts are interpreted in disputes involving regulatory timelines.